Trial Profile
Dose Determination of Taxotere, Eloxatin and Xeloda (TEX) in Combination With Herceptin as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms Her-TEX
- 19 Feb 2011 New trial record
- 14 Jan 2011 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.